Azacitidine‐associated haemorrhagic enteritis in a case of myelodysplastic syndrome: A case report

What is known and objective 5‐Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS). Case description We herein report an 83‐year‐old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrh...

Full description

Saved in:
Bibliographic Details
Published inJournal of clinical pharmacy and therapeutics Vol. 45; no. 4; pp. 828 - 831
Main Authors Hagino, Takeshi, Shinomiya, Wataru, Hidai, Hiroko, Umeda, Miki, Kurimoto, Miwa, Saga, Reina, Tsutsumi, Hisashi, Shibata, Yoshiaki, Akiyama, Hideki, Motomura, Sayuri
Format Journal Article
LanguageEnglish
Published England Hindawi Limited 01.08.2020
Subjects
Aged, 80 and over
azacitidine
Azacitidine - adverse effects
Case reports
colitis
Colonoscopy
Enteritis
Enteritis - chemically induced
Female
Gastrointestinal Hemorrhage - chemically induced
haemorrhagic enteritis
Humans
Intestine
Myelodysplastic syndrome
Myelodysplastic syndromes
Myelodysplastic Syndromes - drug therapy
Ulcers
haemorrhagic enteritis
colitis
myelodysplastic syndrome
azacitidine
Online AccessGet full text

Cover

More Information
Summary:What is known and objective 5‐Azacitidine (AZA) is an agent widely used to treat myelodysplastic syndrome (MDS). Case description We herein report an 83‐year‐old woman diagnosed with MDS who was treated with AZA. She tolerated the first cycle of AZA; however, severe adverse events involving haemorrhagic enteritis with multiple intestinal ulcers developed after the second and third cycles. Additionally, the interval between the administration of AZA and the development of haematochezia shortened with each cycle of AZA. What is new and Conclusion We herein report as‐yet‐undescribed potential side effects, AZA‐associated haemorrhagic enteritis that should be kept in mind.
ISSN:0269-4727
1365-2710
DOI:10.1111/jcpt.13146